S
Stephen J. Richards
Researcher at University of Leeds
Publications - 131
Citations - 8088
Stephen J. Richards is an academic researcher from University of Leeds. The author has contributed to research in topics: Paroxysmal nocturnal hemoglobinuria & Eculizumab. The author has an hindex of 39, co-authored 127 publications receiving 7528 citations. Previous affiliations of Stephen J. Richards include St James's University Hospital & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Charles J. Parker,Mitsuhiro Omine,Stephen J. Richards,Junichi Nishimura,Monica Bessler,Russell E. Ware,Peter Hillmen,Lucio Luzzatto,Neal S. Young,Taroh Kinoshita,Wendell F. Rosse,Gérard Socié +11 more
TL;DR: The primary clinical manifestations of paroxysmal nocturnal hemoglobinuria are hemolytic anemia, marrow failure, and thrombophilia.
Journal ArticleDOI
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Claire Hall,Judith C. W. Marsh,Modupe O. Elebute,Michael P Bombara,Beth E. Petro,Matthew J. Cullen,Stephen J. Richards,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother +10 more
TL;DR: This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.
Journal ArticleDOI
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Andy C. Rawstron,Fiona Bennett,Sheila J.M. O’Connor,Marwan Kwok,James A. L. Fenton,Marieth Plummer,Ruth M. de Tute,Roger G. Owen,Stephen J. Richards,Andrew Jack,Peter Hillmen +10 more
TL;DR: The CLL-phenotype cells found in the general population and in subjects with lymphocytosis have features in common with CLL cells.
Journal ArticleDOI
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard Kelly,Anita Hill,Louise Arnold,Gemma L Brooksbank,Stephen J. Richards,Matthew J. Cullen,Lindsay Mitchell,Dena Cohen,Walter M Gregory,Peter Hillmen +9 more
TL;DR: Eculizumab dramatically alters the natural course of PNH, reducing symptoms and disease complications as well as improving survival to a similar level to that of the general population.
Journal ArticleDOI
Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts
Andy C. Rawstron,Michael J. Green,Anita Kuzmicki,Ben Kennedy,James A. L. Fenton,Paul Evans,Sheila J. M. O'Connor,Stephen J. Richards,Gareth J. Morgan,Andrew Jack,Peter Hillmen +10 more
TL;DR: The monoclonal CLL phenotype cells present in otherwise healthy individuals may represent a very early stage of indolent CLL and should be useful in elucidating the mechanisms of leukemogenesis.